| |
Placebo group (n = 38)
|
uRC group (n = 39)
|
Pa
|
Pb
|
Pc
|
|---|
|
Baseline
|
Follow-up
|
Baseline
|
Follow-up
|
|---|
|
Total-cholesterol (mg/dL)
|
213.86
|
±1.79
|
208.81
|
±3.95
|
214.05
|
±1.50
|
192.82
|
±4.07
|
0.938
|
0.006
| |
|
Change
| |
−5.05
|
±3.84
| | |
−21.23
|
±4.36
| | | |
0.007
|
|
Triglyceride (mg/dL)
|
111.45
|
±6.22
|
119.26
|
±7.70
|
116.05
|
±7.13
|
115.49
|
±8.13
|
0.629
|
0.737
| |
|
Change
| |
−7.82
|
±7.84
| | |
--0.56
|
±7.06
| | | |
0.429
|
|
LDL-cholesterol (mg/dL)
|
135.60
|
±2.58
|
132.55
|
±4.26
|
133.41
|
±2.06
|
117.79
|
±4.34
|
0.508
|
0.018
| |
|
Change
| |
−3.05
|
±3.95
| | |
−15.61
|
±4.16
| | | |
0.032
|
|
Non-HDL-cholesterol (mg/dL)
|
153.71
|
±3.13
|
147.03
|
±4.33
|
153.41
|
±2.63
|
133.28
|
±4.40
|
0.942
|
0.029
| |
|
Change
| |
−6.68
|
±3.30
| | |
−20.13
|
±4.14
| | | |
0.013
|
|
Apolipoprotein B (mg/dL)
|
114.39
|
±2.75
|
120.60
|
±3.82
|
115.17
|
±2.83
|
111.69
|
±3.46
|
0.843
|
0.088
| |
|
Change
| |
6.21
|
±2.84
| | |
−3.48
|
±3.40
| | | |
0.032
|
|
Oxidized LDL (U/L)
|
68.05
|
±3.02
|
66.09
|
±3.47
|
64.31
|
±2.53
|
57.76
|
±2.07
|
0.348
|
0.044
| |
|
Change
| |
−1.95
|
±2.41
| | |
−6.23
|
±1.96
| | | |
0.174
|
- Mean ± SE (Standard Error), Pa-values derived from independent t-test at baseline baseline between the placebo and the uRC group. Pb-values derived from independent t-test at 12-week follow up between the placebo and the uRC group. Pc-values derived from independent t-test for changed value between the placebo and the uRC group. Change value (Δ, delta) represents the change from baseline at follow-up
